Skip to Content


Medically reviewed by Last updated on Aug 11, 2019.


(e REN ue mab)

Index Terms

  • Erenumab-aooe

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Auto-injector, Subcutaneous [preservative free]:

Aimovig: erenumab-aooe 70 mg/mL (1 mL); erenumab-aooe 140 mg/mL (1 mL) [contains polysorbate 80]

Aimovig (140 MG Dose): erenumab-aooe 70 mg/mL (1 mL) [contains polysorbate 80]

Brand Names: U.S.

  • Aimovig
  • Aimovig (140 MG Dose)

Pharmacologic Category

  • Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
  • Monoclonal Antibody, CGRP Antagonist


Erenumab is a human monoclonal antibody that antagonizes calcitonin gene-related peptide (CGRP) receptor function.


Vz: 3.86 L


Via a nonspecific, nonsaturable proteolytic pathway

Time to Peak

~6 days

Half-Life Elimination

28 days

Use: Labeled Indications

Migraine prophylaxis: Preventive treatment of migraine in adults


Serious hypersensitivity to erenumab or any component of the formulation.

Dosing: Adult

Migraine prophylaxis: SubQ: Initial: 70 mg once a month; some patients may benefit from 140 mg once a month

Missed dose: Administer missed dose as soon as possible, and schedule next dose for 1 month from date of the last dose.

Dosing: Geriatric

Refer to adult dosing.


SubQ: For subcutaneous use only; intended for self-administration. Keep out of direct sunlight and allow to come to room temperature for 30 minutes before administration. Do not warm using a heat source (eg, hot water, microwave) and do not shake. Administer in abdomen (avoiding 2 inches around the navel), thigh or upper arm, avoiding areas of skin that are tender, bruised, red or hard. Deliver entire contents of single-use autoinjector or prefilled syringe.


Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light until time of use. If removed from the refrigerator, should be kept at room temperature (up to 25°C [77°F]) in the original carton and used within 7 days. Do not freeze or shake.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

1% to 10%:

Gastrointestinal: Constipation (3%)

Immunologic: Antibody development (3% to 6%)

Local: Injection site reaction (5% to 6%)

Neuromuscular & skeletal: Muscle cramps (≤2%), muscle spasm (≤2%)

Frequency not defined:

Dermatologic: Injection site pruritus

Local: Erythema at injection site, pain at injection site

<1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, hypersensitivity reaction


Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported. Most reactions are mild to moderate and occur within hours after administration, but some may be delayed for >1 week. If a hypersensitivity reaction occurs, discontinue treatment and institute appropriate therapy.

Dosage form specific issues:

• Latex: The packaging (needle shield of auto-injector and needle cap of prefilled syringe) may contain latex.

Monitoring Parameters

Number of monthly migraine days

Pregnancy Considerations

Adverse events were not observed in animal reproduction studies.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience injection site redness, edema, or pain, or constipation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions